Serge Saxonov - Jul 19, 2023 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
Chief Executive Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov
Stock symbol
TXG
Transactions as of
Jul 19, 2023
Transactions value $
-$2,296,029
Form type
4
Date filed
7/21/2023, 05:32 PM
Previous filing
Jul 18, 2023
Next filing
Aug 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $105K +20.8K +2.34% $5.04* 910K Jul 19, 2023 Direct
transaction TXG Class A Common Stock Sale -$2.4M -40K -4.4% $60.03 870K Jul 19, 2023 Direct F1, F2
holding TXG Class A Common Stock 27 Jul 19, 2023 See footnote F3
holding TXG Class A Common Stock 870 Jul 19, 2023 See footnote F4
holding TXG Class A Common Stock 183K Jul 19, 2023 See footnote F5
holding TXG Class A Common Stock 16.3K Jul 19, 2023 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -20.8K -39.09% $0.00 32.5K Jul 19, 2023 Class A Common Stock 20.8K $5.04 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on December 13, 2022.
F2 This transaction was executed in multiple trades at prices ranging from $60.00 to $60.15. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 The shares are held by the Andromeda Trust, for which the Reporting Person serves as trustee.
F4 The shares are held by the Sirius Trust, for which the Reporting Person serves as trustee.
F5 The shares are held by the Y/S Descendants' Trust, for which the Reporting Person serves as trustee.
F6 The shares are held by the Y/S Pot Trust, for which the Reporting Person serves as trustee.
F7 All of the shares subject to the option are fully vested and exercisable as of the date hereof.